Transforming Your Oncology Drug Development
In the last five years, we have helped get 80% of FDA-approved cancer treatments into the hands of patients battling this life-altering disease. Every moment matters when it comes to developing oncology therapeutics, especially yours. Explore our posters, information on our Spotlight Theater presentation, and resources below to learn more about how our comprehensive, integrated oncology portfolio can help you.
See our posters and presentations from the 2025 AACR Annual Meeting below.
| Sunday, April 27, 2025 |
|---|
| Poster #24: Influence of culture conditions and donor material on phenotypic features of PDX-derived breast cancer tumoroid lines Julia Schueler, Charles River in collaboration with IKP |
| Poster #LB009: Safety profile assessment for IND-enabling studies: Bispecific antibodies and antibody-drug conjugates (ADCs) Namrata Jayanth, Research Leader, Advanced Modalities |
| Monday, April 28, 2025 |
|---|
| Poster #1281: Transfer of a PDX Biobank in a humanized setting to enable immune-oncology studies Eva Oswald, Associate Research Director |
| Poster #1285: PBMC-humanized, MHC-deficient NCG mice support growth of human tumor xenografts, do not develop rapid onset GvHD, and provide enhanced performance in oncology studies Steven Bronson, Scientific Product Manager |
| Poster #2532: Utilization of longitudinal ultrasound imaging as a novel pharmacodynamic marker of graft versus host disease progression in mice David Harris, Charles River in collaboration with Revvity, Inc. |
| Poster #2540: Biodistribution and dosimetry of FAPI-46 in mouse model of colorectal carcinoma with PET and SPECT imaging Johanna Rokka, Group Leader Oncology Services |
| Wednesday, April 30, 2025 |
|---|
| Poster #6490: Patient-derived organotypic tumor spheroids (PDOTS) optimize donor selection in allogenic cell therapy development Raluca Dumitru, Charles River in collaboration with Xsphera Biosciences Inc. |
| Poster #6493: Comparison of NK-92MI cell line vs. primary NK cells derived from peripheral mononuclear blood cells Ina Rohleff, Assay Development Scientist |
*Available through The SourceSM
On Target: HER2 Therapies Shaping the Future of Cancer Treatment 
HER2 is a well-known receptor that is a crucial driver of cancer progression, making it an ideal target for cancer therapy due to its role in cell growth and survival pathways. HER2-targeting agents have revolutionized the treatment of HER2 positive cancers, offering personalized and effective options to improve patient outcomes.
Effective therapeutic development depends on selecting the right modality and overcoming scientific, regulatory, and logistical challenges, all of which influence preclinical discovery programs and the overall drug development process.
This presentation explores emerging approaches, including combination therapies that pair HER2-targeted agents with pathway inhibitors or immune checkpoint inhibitors to enhance efficacy. Experts also discuss innovative modalities such as mRNA delivery systems, vaccines, and cell therapies targeting HER2, to broaden the therapeutic landscape.
Advancements in HER2-targeted therapeutics include:
- Monoclonal Antibodies (e.g., Trastuzumab): HER2 signaling blockade and engagement of immune responses via antibody-dependent cellular cytotoxicity (ADCC)
- Bispecific Antibodies: Recruitment of immune cells to HER2+ cancer cells, enhancing cancer cell eradication
- Antibody-Drug Conjugates (ADC): Use of HER2 expression to deliver cytotoxic payloads directly to cancer cells, minimizing off-target effects
- Small Molecule Tyrosine Kinase Inhibitors (TKIs): Inhibition of HER2-related signaling pathways like PI3K/AKT and MAPK to suppress cell survival and proliferation
Speakers at the AACR® Annual Meeting 2025:
- Julia Schueler, Therapeutic Area Lead, Charles River
- Namrata Jayanth, Research Leader BioTherapeutics Discovery, Charles River
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).
Developing an mRNA Nanomedicine Platform to Democratize Therapeutic Antibodies
This presentation demonstrates that mRNA-encoded trastuzumab, delivered via lipid nanoparticles, achieves therapeutic antibody levels comparable to recombinant protein, with superior pharmacokinetics, efficacy, and tolerability in preclinical models—offering a cost-effective alternative to traditional biologics production. The platform could expand patient access to antibody therapies while maintaining functionality in targeting HER2+ tumors and inducing ADCC.
Speaker:
- Louise Brackenbury, Science Director, Charles River
ONCOLOGY TOOL
Oncology Preclinical Study Planning Toolkit
Take control of your efficacy study by finding the right cancer models and exploring study pricing. Let’s see how the users speak about this new tool: “This saves our team a lot of time; we get an idea of pricing without any back-and-forth communication” – Sciences Project manager, Pharma.
PODCAST
Cancer Vaccines, Then and Now
Did you know that the first attempt at a cancer vaccine was in the 1800s, marking a significant milestone in medical history? Our experts, Louise Brackenbury, Dan Rocca, and Mike Templin, discuss the fascinating science behind therapeutic cancer vaccines.
WHITEPAPER
Expedite PDX Efficacy Data
Learn how to combine PDX with next-gen tools, including 3D, machine learning, and in silico technologies, to accelerate your path to the clinic in our white paper.
ON-DEMAND
Pediatric PDX Models and RACE Act Webinar
The RACE Act for Children requires all oncology therapies to be evaluated for efficacy and safety in pediatric cancers prior to receiving FDA approval if the treatment is directed at a relevant molecular target. View our webinar that discusses the RACE act and how Charles River, as part of the ITCCP4 consortium, can provide over 200 annotated, well-characterized, and RACE-compliant pediatric PDX models to accelerate your time to clinic. Learn more about the pediatric PDX models here.
CATALOG/PRICE LIST
2025 Cell Solutions Human and Stem Cells Product Catalog
Charles River is a trusted provider of human immune cells for cell and gene therapies and basic research. Download our 2025 catalog to learn more about our client-focused solutions and best-in-class portfolio of fresh and cryopreserved research use and GMP-compliant human immune cells.
VIDEO
Learn How You Can Accelerate Your Research at CRADL
Building infrastructure is often expensive, time-consuming, and may not be the right approach when conducting early discovery work. Renting at our AAALAC-accredited, full-service turnkey vivarium can help biotech, pharma, and academic organizations expand their research quickly and more efficiently.
RESEARCH MODELS
New Selection of Humanized and Immunodeficient Models
Meet the newest additions to our NCG Plus and Humanized Mice Portfolios, including the humanized HuPBMC NCG-B2M-KO and HuPBMC NCG-MHC-dKO strains that delay graft vs host disease (GvHD) and allows you more time to perform your research. Not sure when you will need your humanized mice? Our PMBC Select Humanization Kit includes pre-validated PBMCs and is compatible with three models: NCG, NCG-B2M-KO and NCG-MHC-dKO, allowing you greater flexibility your study timing.
SOLUTIONS
Rodent Breeding & Colony Management Services
Save time, space, and staffing costs through personalized breeding plans and full-service colony management which includes husbandry work, veterinary consultancy, and health monitoring. Our Internet Colony Management (ICM™) tool allows you to have 24/7 control of your colonies no matter where you are located. How can our colony management experts lighten your research burdens? Explore Breeding Plans.
DEMO TOOL
A Real-Time Solution to Procuring Animal Models
Secure the animals required for your research with our new, lightning-fast ordering experience, offering 24/7 visibility into availability, pricing, and immediate order confirmation.
CATALOG/TOOL
Custom Model Creation
Create a transgenic mouse or rat model tailored to your research needs with your dedicated project manager and option to personalize breeding plans, deliver cohorts of study-ready animals and access your colonies 24/7 through an online portal.
SOLUTIONS
Prevent Contaminants from Affecting your Research
Microbial contaminants of rodent or human origin can unintentionally enter your laboratory and your animals. Safeguard your data and vivarium biosecurity by verifying product integrity through cell line and biologics testing. You can experience a simpler sample submission process with a stabilizing buffer and small sample requirements, samples do not need to be shipped with dry ice – saving time and money. Don’t let contaminates compromise xenograft growth, outcomes, reproducibility, and animal or human welfare. Test your cell lines today.
SOLUTIONS
Fill Staff Roles in Your Vivarium with Insourcing Solutions
If staff turnover or unexpected operational issues are slowing research at your vivarium, our Insourcing Solutions® staffing programs can help you secure experienced animal care technicians, veterinarians, vivarium managers, or other key roles to keep your research on track.
SOLUTIONS
Advance In Vivo Studies Quickly at a CRADL® Vivarium
CRADL®, Charles River’s Accelerator and Development Labs, provide rentable in vivo vivarium space with built-in animal care, IACUC protocol support, and expanded technical research services. You can start with a few study cages, scale cost-efficiently, and pivot quickly as you remain hands-on with your studies while we take care of the daily animal care and facility operations.
Learn more about our oncology services.
Not affiliated with or endorsed by AACR.